- Sort by:
- Browse by:
- Permission not
granted for presentation
New CAR T cells on the horizon
Marcela V Maus
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
- Permission not
granted for presentation
New targets and technologies for CAR-T
Michael Hudecek
University Hospital Wurzburg, Wurzburg, Germany
- Free
- podium video
- audio only
- Audio only
Engineering CAR T Cells to Overcome Resistance
Crystal L Mackall
Stanford University School of Medicine, Stanford, California, Stanford, CA, United States
- Free
- podium video
- audio only
- Audio only
Targeted Protein Degradation as a new Approach to Cancer Drugs
Nathanael S Gray
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- podium video
- audio + slides
- Some slides withheld
Exploiting E3 ligases for target validation and drug discovery: What have we learnt so far?
Rajesh Chopra
The Institute of Cancer Research, London, United Kingdom
- Free
- Coming soon
- Some slides withheld
The zinc-finger degrome
Nicolas H. Thoma
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
- Free
- slides video
- audio + slides
- All slides included
A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor
Mark R. Kelley
Indiana University School of Medicine, Indianapolis, IN, United States
- Free
- slides video
- audio + slides
- All slides included
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S Heist
Massachusetts General Hospital, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno
START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
- Permission not
granted for presentation
T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
Maximizing the potential of bispecific antibodies for cancer drug development
Paul W H I Parren
Leiden University Medical Center and Lava Therapeutics, Utrecht, Netherlands
- Permission not
granted for presentation
Rational cancer & immune cell therapy combinations a functional genomics approach
Daniel Peeper
Netherlands Cancer Institute, Amsterdam, Netherlands
- Free
- slides video
- audio + slides
- All slides included
Discovery and development of HIF-2a inhibitors for the treatment of clear cell renal cell carcinoma
Eli Wallace
Peloton Therapeutics, Inc., Dallas, TX, United States
- Permission not
granted for presentation
Targeting the opposing roles of IFN for cancer immunotherapy
Andy J. Minn
Abramson Family Cancer Research Institute, Philadelphia, PA, United States
- Free
- Coming soon
- Some slides withheld
Functional genomics approaches to the discovery of paralog dependencies in cancer
William R Sellers
Broad Institute of MIT and Harvard, Cambridge, MA, United States
- Free
- audio + slides
- Some slides withheld
Functional genomics approaches to identify targetable dependencies in cancer cells
Mathew Garnett
Wellcome Sanger Institute, Cambridge, United Kingdom
- Permission not
granted for presentation
Discovering regulators of the immune response to cancer using functional genomics
W Nicholas Haining
Merck & Company, Boston, MA, United States